Sertraline in the treatment of minor depression in nursing home residents: a pilot study
✍ Scribed by Jules Rosen; Benoit H. Mulsant; Bruce G. Pollock
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 90 KB
- Volume
- 15
- Category
- Article
- ISSN
- 0885-6230
No coin nor oath required. For personal study only.
✦ Synopsis
Minor' depression aects up to 50% of residents in long-term care facilities and is associated with considerable discomfort, disability and risk of morbidity. Despite the prevalence of this problem, few studies addressing the treatment of these patients have been conducted. In an open clinical trial, 12 nursing home residents who met the DSM-IV description for minor depressive disorder were treated with sertraline for 6 weeks. Adverse eects and clinical response were monitored. All residents tolerated their medication without any signi®cant side-eects. At the completion of the study, the Hamilton Depression Rating Scale and Global Assessment Scale change scores both indicated signi®cant improvement and 75% of the residents met criteria for `remission'. This preliminary study provides evidence that nursing home residents with minor depression tolerated treatment with sertraline and improved clinically.
📜 SIMILAR VOLUMES
The objectives of this study were ®rst to compare the responses to moclobemide and sertraline in melancholic and nonmelancholic major depressive patients and secondly to compare the responses of melancholic and nonmelancholic patients in general. Sixty-three patients, with diagnosis of major depress
A double-blind, placebo-controlled study was conducted to assess the relative efficacy and tolerability of fluoxetine and desipramine in depressed, human immunodeficiency virus (HIV)-positive women. Although difficulty in the recruitment and retention of participants led to insufficient power to det
This double-blind randomized pilot study aimed to compare the ecacy and the tolerability of pirlindole (150±225 mg/day), a reversible inhibitor of monoamine oxidase A, and mianserin (60±90 mg/day) in the treatment of major depression. Forty patients were included in the trial (20 pirlindole and 20 m